Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

17%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
5(83.3%)
Phase 4
1(16.7%)
6Total
N/A(5)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT04800042Not ApplicableUnknown

Study of the Prevalence of Iron Deficiency in Patients With Scheduled Major Surgery (CARENFER PBM)

Role: lead

NCT04123145Not ApplicableUnknown

Study of the Prevalence of Iron Deficiency in Patients With Chronic Renal Failure But Non-Dialysis (CARENFER IRC-ND)

Role: lead

NCT04123990Not ApplicableUnknown

Study of the Prevalence of Iron Deficiency in Patients With Chronic Inflammatory Bowel Disease

Role: lead

NCT03924258Not ApplicableUnknown

Study of the Prevalence of Iron Deficiency in Patients With Heart Failure

Role: lead

NCT03924271Not ApplicableUnknown

Prevalence Study of Iron Deficiency in Patients With Cancer

Role: lead

NCT03831633Phase 4Unknown

Comparative Effectiveness of AKYNZEO® and Standard of Care (Including EMEND®) for the Prevention of Nausea and Vomiting (CINV) in Cancer Patients

Role: lead

All 6 trials loaded